Resectable Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting Phase 2 Trials for Pembrolizumab (DB09037)
Also known as: Resectable Pancreatic Ductal Adenocarcinoma
| Indication | Status | Phase |
|---|---|---|
| DBCOND0115304 (Resectable Pancreatic Ductal Adenocarcinoma (PDAC)) | Recruiting | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT03727880 | Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | Treatment |